Postoperative infections after lung resection postoperative infections, lung resection
Conditions
Interventions
Miya BM, a daily dose of 3 g, divided into 3 times a day, administered orally after meals
probiotics
Sponsors
Murakami Junichi
Murakami Junichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Outpatients or hospitalized patients scheduled for thoracoscopic anatomical lung resection (lobectomy or segmentectomy) for pulmonary lesions (2) Patients suspected of primary lung cancer by CT or PET-CT, or diagnosed with primary lung cancer by bronchoscopy or CT-guided biopsy (3) Patients aged 20 years or older at the time of informed consent (4) Patients who have given written informed consent of their own free will after receiving sufficient explanation about participating in this study
Exclusion criteria
Exclusion criteria: (1) Patients with a history of allergy to probiotics (2) Patients with a history of side effects due to oral administration of probiotics (3) Patients who have already received continuous administration of probiotics (4) Patients who are currently taking probiotics regularly as guidance-required or over-the-counter drugs (5) Patients undergoing treatment for any infectious disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All postoperative infections including surgical site infections (SSIs) | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of adverse events due to Miya BM, all postoperative complications excluding postoperative infections after lung resection (CTCAE v5.0-JCOG grade2 and more), chest tube duration, hospital duration, body temperature and body weight, blood test (white blood cell count, white blood cell differential, CRP, serum albumin level, serum total cholesterol level, serum cholinesterase level) | — |
Contacts
Public ContactJunichi Murakami
Yamaguchi University Hospital
Outcome results
None listed